Immune dysregulation in major depressive disorder: biomarker heterogeneity, sexual dimorphism, and clinical manifestations

Introduction: Major Depressive Disorder (MDD) is a prevalent and debilitating psychiatric condition characterized by persistent low mood, anhedonia, and a diverse range of cognitive and neurovegetative symptoms, and it is the result of interactions between genetic predisposition, environmental stressors, and biological dysregulation. It is a leading cause of global disability, yet its pathophysiological heterogeneity remains a significant barrier to effective treatment, with approximately 30% of patients with this disorder remaining treatment-resistant. Emerging evidence has shifted focus towards the immune system, suggesting that dysregulation of both innate and adaptive immunity plays a causative role in depression. This “inflammatory hypothesis” postulates that systemic low-grade inflammation is not merely a comorbid feature but a critical disease modifier that leads to susceptibility and inhibits favorable prognosis. However, the exact magnitude of these alterations and whether they define a specific subgroup or represent a general distribution shift across the MDD population remain central questions in clinical neurobiology.

Objective: This review aims to synthesize recent meta-analytic data and systematic findings to quantify the prevalence of low-grade inflammation in Major Depressive Disorder, identify symptom-specific associations, and evaluate how sex-based differences influence inflammatory profiles and treatment implications.

Methods: A non-systematic review was conducted based on systematic reviews and meta-analysis, using the keywords “CRP”, “inflammation”, “depression” and “biomarker” on the platform PubMed.

Results: The findings confirm that Major Depressive Disorder is substantially associated with a pro-inflammatory state. Meta-analytic evidence shows significantly higher levels of C-Reactive Protein (CRP), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-alpha) in depressed patients compared to healthy controls. Particularly, the prevalence of low-grade inflammation (CRP > 3 mg/L) in depression is approximately 27%, with over 58% of patients exhibiting mildly elevated CRP (>1 mg/L). The odds ratio for presenting low-grade inflammation in MDD is 1.46 compared to controls. Deconstructing depression reveals that inflammation is primarily linked to neurovegetative symptoms (e.g., sleep disturbance, fatigue, and appetite changes) rather than cognitive symptoms. Moreover, significant sex differences emerge: elevated CRP and IL-6 appear more pronounced and statistically significant in females with depression compared to the male patients. In some markers like CRP and IL-12, reduced variability suggests a greater homogeneity toward an inflammatory phenotype in a specific subgroup, while others indicate a general shift in immune distribution across the MDD spectrum. [1], [2]

Conclusion: Inflammation is a key mediator in the pathogenesis of MDD, affecting at least a quarter of the patient population. The association between immune activation and specific neurovegetative clusters, alongside evident sex-specific inflammatory profiles, underscores the need for a personalized approach in psychiatry. Identifying these “inflammatory endotypes” through standardized biomarkers like CRP, provides a critical opportunity to transition from a “one-size-fits-all” model to precision medicine. Controlling inflammation, whether triggered by stress or microbiome changes, represents a vital therapeutic edge for improving outcomes in patients who do not respond to conventional antidepressant therapies.

References

1. Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM (2019). Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychological Medicine 49, 1958–1970. https://doi.org/10.1017/S0033291719001454
2. Osimo, Emanuele F., et al. «Inflammatory Markers in Depression: A Meta-Analysis of Mean Differences and Variability in 5,166 Patients and 5,083 Controls». Brain, Behavior, and Immunity, vol. 87, julho de 2020, pp. 901–09. DOI.org (Crossref), https://doi.org/10.1016/j.bbi.2020.02.010.